Journal article : Review
Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight
- Abstract:
- The field of asthma has undergone a dramatic change in recent years. Advances in our understanding of type 2 airway inflammation have driven the discovery of monoclonal antibodies targeting specific aspects of the immune pathway. In landmark trials, these drugs have shown efficacy in reducing asthma attacks and exposure to oral corticosteroids, important causes of morbidity in people with asthma. Our review explores the key features of type 2 inflammation in asthma and summarizes the clinical trial evidence of the novel monoclonal antibody treatments and future avenues for treatment.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.1084/jem.20221212
Authors
- Publisher:
- Rockefeller University Press
- Journal:
- Journal of Experimental Medicine More from this journal
- Volume:
- 220
- Issue:
- 7
- Article number:
- e20221212
- Place of publication:
- United States
- Publication date:
- 2023-06-02
- Acceptance date:
- 2023-05-12
- DOI:
- EISSN:
-
1540-9538
- ISSN:
-
0022-1007
- Pmid:
-
37265457
- Language:
-
English
- Keywords:
- Subjects:
- Subtype:
-
Review
- Pubs id:
-
1355566
- Local pid:
-
pubs:1355566
- Deposit date:
-
2023-07-26
- ARK identifier:
Terms of use
- Copyright holder:
- Howell et al.
- Copyright date:
- 2023
- Rights statement:
- © 2023 Howell et al. This article is available under a Creative Commons License (Attribution 4.0 International).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record